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Acute lymphoblastic leukemia (ALL) comprises a highly
heterogeneous set of diseases that are deﬁned by their cells
of origin, stage of maturation arrest, and the underlying
oncogenic driver pathways. Subclassiﬁcation of lymphoid
neoplasms is often based on the presumed cell of origin
based on T and B progenitor gene expression. In general, T-
ALL has a worse prognosis and requires more intensive
therapies to achieve similar remission rates as their B-ALL
counterparts [1, 2]. Given the common origin of these cells
from committed lymphoid progenitors, investigators have
suggested that the differences in clinical presentation of T-
ALL and B-ALL are likely accounted for by the underlying
differences in the oncogenic drivers of transformation. For
example, T-ALLs often express oncogenic transcription
factors and acquire activating NOTCH1 mutations that
elevate MYC activity to drive tumor initiation and main-
tenance [3, 4]. By contrast, B-ALLs are more frequently
driven by chromosomal rearrangements that create fusion
oncogenes and have recurrent chromosomal aberrations [5].
Despite these differences, MYC is also commonly activated
in human B-ALL [6] and drives leukemia initiation and
growth in mouse models [7], suggesting important roles for
this pathway in both T-ALL and B-ALL. It is clear that
underlying oncogenic drivers exert important roles in reg-
ulating the functional characteristics of leukemia cells,
including regulating the overall fraction of leukemia stem
cells (LSCs) that drive continued tumor growth and relapse
following therapy resistance. Yet, to date, the effect of cell
lineage on inﬂuencing LSC number and self-renewal is
largely unknown, accounted for in part, by lack of experi-
mental models to address these questions.
Here, we have used a zebraﬁsh transgenic model of Myc-
induced ALL to investigate the roles of cell lineage on
modulating growth, aggression, and LSC frequency in T, B,
and biphenotypic ALL. Previously, the rag2-Myc trans-
genic zebraﬁsh model has been exploited to develop robust
T-ALL models when introduced into AB strain zebraﬁsh
[8]. Moreover, ﬁndings in this model have led to signiﬁcant
new insights into human T-ALL [9, 10]. Using this same
transgenic approach, we had previously generated leuke-
mias in syngeneic CG1 strain zebraﬁsh and performed
large-scale cell transplantation assays to assess latency and
LSC frequency differences between intra-tumoral and inter-
tumoral clones [9]. These experiments required implanting
single LSCs into large cohorts of transplant animals, thus
creating monoclonal tumors (schematic shown in Fig. 1a).
Each monoclonal leukemia was then assessed for latency of
regrowth and LSC frequency using large-scale limiting
dilution cell transplantation [9]. From these previously
published studies, we uncovered that clonal heterogeneity is
common in T-ALL, with individual leukemia clones exhi-
biting striking differences in latency, aggression, and LSC
frequency, and also identiﬁed the PI3-kinase/AKT pathway
as a driver of elevated growth and LSC frequency in both
zebraﬁsh and human disease [9].
Using this previously generated library of well-annotated
monoclonal ALLs deﬁned by Blackburn et al. [9], we
selected leukemias that harbored high (>1%) and low
numbers of LSCs (<1%, Supplemental Table 1) [9]. These
leukemias are reported using the same nomenclature from
Blackburn et al [9] and were subjected to bulk RNA
sequencing. Principal Component Analysis (PCA) was
then performed to identify molecular differences between
clones. Principal Component 1 (PC1) and PC2 represent the
top two gene expression proﬁles derived as dimensions
from Principal Component Analysis. This analysis
These authors contributed equally: Sowmya Iyer, Sara P. Garcia.
* David M. Langenau
dlangenau@mgh.harvard.edu
Extended author information available on the last page of the article
Electronic supplementary material The online version of this article
(https://doi.org/10.1038/s41375-018-0130-0) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
conﬁrmed that replicate samples always segregated with
one another, and more importantly, identiﬁed two easily
discernable molecular subgroups of leukemia, labeled group
1 (in blue) and group 2 (in red, Fig. 1b). Interestingly, the
two clusters in the PCA corresponded to signiﬁcant differ-
ences in tumor behavior: group 1 leukemias had
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signiﬁcantly shorter latency of leukemia regrowth in trans-
planted ﬁsh and had more LSCs when compared with group
2 (Fig. 1c, Wilcoxin Rank Order Test). Hierarchical clus-
tering using the 100 most highly variable, positively and
negatively correlated transcripts identiﬁed from PC1,
afﬁrmed the classiﬁcation of two molecularly distinct ALL
groups (Fig. 1d, Supplemental Table 2). Unexpectedly,
GSEA analysis uncovered that PC1 was deﬁned by T and B
cell lineage genes, with T cell genes being highly expressed
in the fast growing and high LSC containing leukemias
while B cell genes were conﬁned to leukemias with longer
latency and low LSCs (Fig. 1d, e). PC2 genes comprised
proliferation genes (Supplemental Table 3), identifying T-
ALL clone 8.3 as having lower overall proliferative
potential and likely accounting for its low percentage of
LSCs.
Given that the rag2-Myc transgenic model had never
generated B-ALL in other strains of zebraﬁsh [8–11], we
next sought to independently conﬁrm cell lineage by
assessing T and B cell receptor expression. As expected, all
group 1 leukemias expressed tcr-beta, with most expressing
a single unique variable region, independently conﬁrming
(1) derivation from a single LSC, (2) monoclonality of each
ALL, and (3) correct classiﬁcation as T-ALL. In contrast to
what is seen in human, the tcrbc1 and c2 constant regions
are not excised from the zebraﬁsh genomic locus following
receptor recombination and hence each can be used to
create a functional receptor following splicing. As reported
in human, a small subset of T cells can also express two
TCR-beta chains [12], likely accounting for the expression
from both recombined alleles in T-ALL clone 15.2.
Meanwhile, clones 9.2 and 10.2 failed to express tcr-beta or
other T cell receptors including alpha, delta, and gamma,
but rather expressed the constant region of IgHC (Fig. 2a).
Importantly, only the IgHC constant regions for IgM, IgD,
and IgZ were expressed while the variable gene segments
were not, suggesting that the IgHC locus is open but that
rag1/2-mediated receptor recombination had not yet
occurred in these B-ALLs (Supplemental Table 4). Addi-
tional gene expression analysis showed that T-ALLs were
arrested at a CD4+/CD8+cortical thymocyte stage, as pre-
viously described [13], while B-ALLs 9.2 and 10.2 express
genes pro-B marker genes including rag1/2, ebf1, pax5, dntt
(tdt), and cd79a (Fig. 2b). Remarkably, Myc expression
levels were not signiﬁcantly different between T-ALL and
B-ALLs (Supplemental Figure 1), failing to account for the
observed differences in LSC frequency and latency differ-
ences between leukemias. Altogether, these results show
that CG1 strain zebraﬁsh develop both Myc-induced T-ALL
and B-ALL and that cell of origin likely has important roles
in regulating LSC frequency and overall aggression. Given
that all previous leukemia generated in this model were
suggested to be T-ALLs, our reﬁned analysis has led to the
unexpected ﬁnding of B-ALL in a small fraction of
CG1 strain ﬁsh and suggest mis-classiﬁcation of a subset of
leukemias in our previous work [9].
In completing our receptor gene expression studies, we
also observed that leukemia 12.2 had both T and B cell
characteristics. This leukemia recombined and expressed
tcr-beta, failed to express IG heavy chain, and exhibited
expression of both T and B lineage markers along with
unique genes not found in the other leukemias (Fig. 2b).
These data raised the interesting possibility that leukemia
12.2 was a mixed phenotypic acute leukemia (MPAL). In
fact, the World Health Organization recently published a
revision for acute leukemia classiﬁcation that now includes
new criteria for classiﬁcation and diagnosis of MPAL,
uncovering that MPALs occur in ~2–5% of pediatric and
adult acute leukemia [14]. Because clinical MPAL cases
can be further subclassiﬁed into either bilineal, a leukemia
that contains two distinct blast populations, or biphenotypic
ALL, a leukemia that contains a single blast population that
expresses multiple lineage markers [14], we next used
single-cell gene expression analysis to clarify if leukemia
12.2 was a mixture of two distinct blast types or if they were
biphenotypic [13]. Principal component analysis showed
that tumor 12.2 was molecularly distinct and separated
cleanly into its own PCA grouping when compared with
non-transformed thymic T cells, marrow-derived B cells
and three independent T-ALL clones (Fig. 2c). Remarkably,
gene expression correlation analysis revealed that individual
leukemia cells from 12.2 indeed expressed both T and B
cell genes, conﬁrming assignment as biphenotypic B/T-
ALL (Fig. 2d). Human biphenotypic B/T-ALL is exceeding
rare and to date has been characterized by CD3ε T cell
marker expression in combination with CD19 and either
CD79a, CD22, or CD10 B cell marker expression [15].
Zebraﬁsh orthologs to many of these genes have yet to be
fully described and antibodies are lacking. Moreover,
detailed transcriptional analysis of human B/T-ALL has yet
to be completed, obviating direct comparison of human and
Fig. 1 Myc-induced ALLs comprise two distinct molecular subtypes
that differ in latency and leukemia stem cell number. a A schematic of
the cell transplantation screen previously used to identify differences
in latency and leukemia stem cell number (LSCs) between ALL clones
(Blackburn et al. [9]). ** denotes p= 0.0065, by Wilcoxon rank order
test. b RNA sequencing and principal component analysis of ALLs
with high and low LSCs. All samples, except for 14.1.1.1 and 8.4.1.1,
were assessed as technical replicates. Group 1 leukemias are demar-
cated by blue shading, while group 2 leukemias have been shaded in
red in panels b, c, and d. c The two molecularly-deﬁned subgroups
differ in latency and LSC frequency when assessed by Wilcoxon Rank
Sum Test. d Heat map and hierarchical clustering of group 1 and group
2 leukemias showing the top 100 genes positively and negatively
correlated with PC1. e Gene set enrichment analysis using genes
positively and negatively correlated with PC1. Genes positively cor-
related with PC1 are associated with T cells while those found to be
negatively correlated with PC1 were B cell associated genes
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zebraﬁsh disease at this time. Future experiments will assess
if there are species-speciﬁc differences in this disease entity
or, more importantly, if common molecular programs drive
their growth.
In summary, our results have uncovered unexpected
zebraﬁsh strain differences in driving cell fate decisions in
the genesis of ALL and provide new and exciting avenues
for modeling B-ALL and biphenotypic B/T-ALL using
Fig. 2 B cell molecular programs drive lower aggression and stem cell
activity in acute lymphoblastic leukemia. a T cell receptor beta and Ig
heavy chain expression within individual ALL clones. Left plot shows
only the tcrb variable regions that were expressed within each clone.
Right plot displays expression for each tcrb and IgHC constant region
for clones in the same order as presented on the left. b Heatmap
showing gene expression of T and B cell associated genes and genes
speciﬁcally expressed in biphenotypic B/T-ALL clone 12.2. c Single-
cell quantitative real-time PCR and principal component analysis
visualization showing that 12.2 represents a clearly distinct molecular
subtype when compared with T-ALL clones 8.4.1.1, 13.1.1.1, and
14.1.1.1, and normal rag2-dsRed+thymic T cells and marrow-derived
B cells. d Gene expression correlation comparing T vs B cell genes
within individual ALL cells (x-axis vs. y-axis, respectively), con-
ﬁrming that clone 12.2 is a bi-phenotypic B/T-ALL
E. G. Garcia et al.
zebraﬁsh models. To date only a single report has char-
acterized the development of a B cell leukemia model in the
zebraﬁsh and no robust models of biphenotypic B/T-ALL
have been reported [16]. Perhaps more importantly, we
have used our zebraﬁsh model to show that cell lineage is a
major determinant of oncogenic phenotypes in ALL, with T
cell pathways driving elevated growth, aggression, and LSC
self-renewal. By contrast, intrinsic B cell pathway activa-
tion leads to reduced growth and leukemia stem cells. These
results provide new insights into the clinical differences
between T-ALL vs. B-ALL and suggest that underlying
differences in cell of origin likely account for superior
clinical outcome in B-ALL patients, with the prediction that
B cell lineage leukemias will have lower aggression and
overall numbers of relapse driving LSCs.
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